This week’s Thursday discussion covered two important subjects: the difficulties of reducing long-term steroid treatment, and the future of our online patient meetings. Both conversations highlighted the importance of listening to patients, respecting their choices and recognising the value of their experiences.

Steroid tapering: when does the cost become too high?

Our first discussion explored the difficulties of reducing long-term prednisolone treatment, particularly for people whose natural cortisol production has been suppressed.

Patients described prolonged tapering, sometimes extending over many months, accompanied by widespread muscle and joint pain, fatigue, weight loss and a substantial reduction in quality of life.

What emerged was not simply frustration with unpleasant symptoms. There was a more fundamental question: is reducing prednisolone always worth the impact it can have on everyday life?

People have responsibilities. They may need to work, care for relatives, manage their homes or maintain some degree of independence. When reducing steroids leaves someone struggling to fulfil those responsibilities, the consequences extend well beyond physical discomfort.

Patients recognised that long-term steroid treatment has risks and that reducing unnecessary exposure is important. Some also described benefits during the reduction process, including needing fewer courses of antibiotics, although that does not necessarily establish that tapering caused the improvement.

But they questioned whether the process sometimes becomes too focused on achieving a lower dose, without sufficient consideration of what patients are experiencing along the way.

Are we pushing too hard?

Glucocorticoid withdrawal can cause significant muscle and joint pain, fatigue and reduced wellbeing. Adrenal insufficiency can produce overlapping symptoms, and the underlying inflammatory condition may also become more active as treatment is reduced.

Distinguishing these possibilities is important because they may require different responses.

A very low cortisol result does not necessarily mean that every further dose reduction is inappropriate, but it does require careful interpretation, particularly when the patient is approaching physiological replacement doses.

The discussion also highlighted concern about how symptoms are assessed. A patient does not need to be experiencing an adrenal crisis to have a seriously impaired quality of life. Nor does the absence of vomiting exclude clinically significant adrenal insufficiency or an adrenal crisis.

The group raised an important question for clinicians:

When a patient is struggling to function during a prolonged steroid taper, should the pace and objectives of treatment be reconsidered together?

This does not mean abandoning the goal of reducing unnecessary steroid exposure. It means recognising that treatment success involves more than the dose recorded on a prescription.

For patients, success may also mean being able to get out of bed comfortably, care for family members, maintain relationships, work where possible and enjoy everyday activities.

Can patients ask to slow down?

An important question arising from our discussion was whether patients feel able to tell their doctors when steroid tapering is becoming too difficult.

Patients may understand and agree with the reasons for reducing prednisolone, yet find that the pain, fatigue and disruption to everyday life become increasingly difficult to tolerate.

It can be hard to say, “This is too much. Can we slow down?”

Some people may worry that their doctor will think they are unwilling to follow treatment advice, or that they are failing to make progress. Others may assume that the tapering schedule is fixed and cannot be changed.

But there is not usually a clinical requirement to reduce prednisolone as quickly as possible regardless of the consequences.

Reducing unnecessary steroid exposure is important because long-term treatment carries significant risks. However, the appropriate pace depends on the underlying disease, current dose, adrenal function and how the patient is coping.

International endocrine guidance recognises that severe glucocorticoid withdrawal symptoms may justify temporarily returning to the last tolerated dose and extending the tapering schedule, under medical supervision.

As doses approach normal physiological replacement levels, particular care is needed because the body’s own cortisol production may not yet have recovered.

Patients should therefore feel able to explain how the taper is affecting their lives and ask whether the plan can be reviewed.

For example:

“I understand why reducing prednisolone matters, and I want to continue working towards that. But at the moment the pain and exhaustion are making it difficult to manage my everyday responsibilities. Could we review whether the taper needs to be slower?”

This is not a request to abandon treatment or an invitation to change doses independently. It is an opportunity for shared decision-making, including assessing whether symptoms reflect withdrawal, adrenal insufficiency or worsening of the underlying condition.

There may be good clinical reasons for continuing a particular schedule, but these should be explained and balanced against the patient’s wellbeing.

A successful taper should not be judged solely by how quickly the dose falls, but also by whether the patient can remain safe and maintain an acceptable quality of life along the way.

Can one illness undo months of progress?

Another concern was the possibility that an illness could undo many months of difficult steroid tapering.

For someone who has spent a long time gradually reducing prednisolone, the prospect of needing higher steroid doses during an infection or other illness can be deeply discouraging. Patients questioned whether a single episode could really mean starting the whole process again.

There is an important distinction here.

People with adrenal insufficiency may need temporary increases in glucocorticoid treatment during illness to prevent adrenal crisis. This is an essential safety measure, not a failure of treatment.

A short period of increased steroid cover does not automatically reverse months of adrenal recovery or mean that the entire taper must begin again. The effect depends on the dose, duration and individual circumstances.

A prolonged course of higher-dose prednisolone to treat a worsening respiratory condition is different. This may suppress adrenal function further and complicate the subsequent taper.

The discussion highlighted the importance of explaining what progress actually means, how adrenal recovery is assessed and what happens to the treatment plan when someone becomes unwell.

Patients need to know that following their prescribed sick-day rules is protecting their health, not failing in their efforts to reduce steroids.

What should clinicians take from this?

The discussion underlined the importance of shared decisions, clear plans for assessing adrenal recovery and taking seriously the cumulative burden of a long and difficult taper.

Patients should not alter steroid doses independently, but significant or worsening symptoms deserve clinical reassessment rather than simply being accepted as an inevitable part of withdrawal.

Perhaps the most important distinction is this:

Clinicians may measure progress by the reduction in steroid dose. Patients may measure progress by whether they can still live their lives.

Both matter, and successful treatment needs to take account of both.

What do we really need from our patient meetings?

Our second discussion took a different direction.

NAC has offered online meetings for people affected by aspergillosis for many years. We currently have informal Tuesday social meetings, Thursday discussions and a longer monthly Friday meeting.

But are these still the right meetings? Who benefits from them? And why do so many people choose not to attend?

We began by considering what people value about meeting others living with aspergillosis.

For some, the greatest benefit is companionship and the reassurance of speaking to someone who understands their experiences. Others value learning about treatments, hearing about new research, sharing practical ideas or simply knowing that they are not alone.

Meetings can also provide hope, confidence and a sense of purpose.

However, not everyone wants or needs these things from a group meeting, and that is an equally important consideration.

Why don’t more people attend?

There are many possible reasons why someone might not join an online patient meeting.

Some are practical. People may be working, caring for relatives, managing unpredictable symptoms or struggling with technology.

Others are more personal.

Some people feel they are managing well and do not need additional support. Some prefer not to learn more about their illness, particularly if hearing about complications or other people’s difficulties might cause anxiety.

Others may simply prefer to keep their health private.

Joining a meeting with strangers can involve revealing something deeply personal. Even if nobody is expected to discuss their medical history, attending can feel like making an illness part of one’s social identity.

We should respect that choice.

There may also be uncertainty about what actually happens during a meeting. Will people be expected to speak? Will they be asked personal questions? Will everyone else know more about aspergillosis than they do?

For someone who has never attended, these uncertainties can be substantial.

Do people have to become desperate before seeking support?

One particularly striking observation from our discussion was that some participants had only decided to attend meetings when they were becoming desperate for help.

This raises an important question.

Could people benefit from meeting others earlier, before they reach a point of serious difficulty?

Peer support is not necessarily about coping with a crisis. It can be about learning, gaining confidence, discovering practical ideas and understanding what help is available.

At the same time, we should not assume that everyone needs a support group.

A successful patient support service is not one that everyone uses. It is one that people know about, trust and can access when they want or need it.

A new Wednesday evening drop-in

One practical outcome of our discussion was the decision to test an evening meeting.

All our existing regular meetings take place during the day. This may make them inaccessible to people who work or have daytime commitments.

We therefore propose a new informal evening drop-in:

Wednesday 18 November 2026, 6–7 pm (UK time)

The meeting will be online and deliberately informal.

People will be welcome to join at any point, stay for as long as they wish, and leave whenever they need to. There will be no formal presentation or expectation to contribute.

Participants can simply listen, ask questions, meet others or suggest what they might find useful from future evening meetings.

This will be a trial to discover whether a different time and format helps us reach people who cannot attend existing sessions.

We will share joining information through our usual meeting channels.

Something unexpected: we’ve become a team

Perhaps the most interesting part of the discussion was recognising how the Thursday group itself has developed.

Over time, regular participants have become more than people attending a support meeting.

They share knowledge, compare experiences, identify problems, challenge assumptions and suggest ways of improving information and care for other patients.

In many respects, they have become an informal team of patient advocates.

This has happened naturally, without formal roles, committees or expectations.

The group provides mutual support, but it also contributes a collective understanding of living with aspergillosis that is difficult to obtain from clinical appointments alone.

This is particularly valuable when developing patient information, identifying gaps in care and helping professionals understand the realities of managing a long-term condition.

Of course, regular participants do not represent every person living with aspergillosis. Their experiences and priorities may differ from those of people who never attend.

That makes it important to seek wider perspectives whenever we develop resources or recommendations intended for the broader patient community.

From support meetings to a community that contributes

Our conversation suggested a wider possibility for the future.

What began as patient support meetings could continue developing into a patient community that supports, learns and contributes together.

People might contribute by sharing experiences, suggesting meeting topics, reviewing patient information, helping newcomers feel welcome or identifying questions that deserve more attention from researchers and clinicians.

One example is our developing article about the hidden work of living with aspergillosis between medical appointments. We hope patient experiences will help explain to respiratory professionals the effort involved in managing symptoms, medicines, fatigue and everyday life.

But contribution should always be an opportunity, never an obligation.

Some people want to help develop projects. Others simply want to listen, learn or enjoy a conversation with people who understand.

All these forms of participation have value.

What happens next?

Our discussion has suggested several useful next steps:

1. Test the Wednesday evening drop-in to see whether it makes meetings more accessible to people with daytime commitments.
2. Learn more about non-attendance, including why people have stopped attending or have never felt the need to join.
3. Make meetings feel easier to approach, explaining clearly that people can listen without sharing personal information.
4. Explore ways for patients to contribute, including helping develop information and educational resources.
5. Preserve the informal and supportive atmosphere that has allowed the existing group to develop naturally.

We also need to recognise that attendance numbers alone cannot capture the value of these meetings.

A small group may provide substantial mutual support and contribute ideas that ultimately benefit many more patients.

Equally, someone who attends once, gains reassurance and never needs to return may have received exactly what they needed.

A final thought

Living with aspergillosis is different for everyone, and so are people’s needs for information, support and companionship.

Some want regular contact with others. Some prefer occasional conversations. Some want to contribute to improving care. Others are perfectly happy managing independently.

Our aim should not be to bring everyone into the same kind of meeting.

It should be to create a welcoming, flexible community where people can find information, understanding, hope and opportunities to contribute — on their own terms.

And perhaps the most encouraging discovery from this week’s conversation is that we already have the beginnings of that community.

Thursday Sessions are informal online discussions for people affected by aspergillosis. They provide opportunities to share experiences, learn from one another and explore issues that matter to patients. The views discussed are personal experiences and should not be taken as medical advice or as representative of everyone living with aspergillosis.

Interested in joining us? Visit our online patient meetings page for information about our meetings and how to participate.

Path: Start » NAC & Guidance » Events & Recordings » Patient Meeting Recordings » Thursday Sessions: From patient support to a community that contributes